PRGO Stock Recent News

Perrigo's (PRGO) new products and products added through acquisitions are expected to have aided the top line in the soon-to-be-reported quarter.

DUBLIN , April 23, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2024 financial results on Tuesday, May 7 th, 2024, and host a conference call beginning at 8:30 A.M. (EDT). The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 888-664-6383, International 416-764-8650, and reference ID # 910565.

After nearly a decade of struggles, Perrigo is poised to turn the corner under the leadership of a new CEO who is only nine months in the seat. Infant formula woes will be resolved in Q2 and comparisons year over year will start to be favorable in the second half of 2024. Focus on total shareholder returns to be unveiled at the investor day in the fall could be a catalyst for the shares.

Perrigo (PRGO) reports mixed fourth-quarter 2023 results. Management issues fresh financial outlook for 2024, which were below our expectations.

While the top- and bottom-line numbers for Perrigo (PRGO) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Perrigo Company focuses on the consumer self-care market and aligns with the growing trend of investing in well-being products. The company has faced regulatory issues with its baby formula production, leading to FDA warning letters and recalls. Appointing a new CEO and implementing a strategic plan to increase organic net sales and improve shareholder value may present a buying opportunity, but execution risks should be considered.

Perrigo (PRGO) reports dismal third-quarter 2023 results. Management lowers guidance for earnings and sales.

Perrigo Co. Plc's stock PRGO, -0.97% fell 14% early Tuesday, after the consumer self-care and wellness products maker posted weaker-than-expected third-quarter sales and lowered its guidance. Dublin, Ireland-based Perrigo had net income of $14.2 million, or 10 cents a share, for the quarter, after a loss of $49.4 million, or 37 cents a share, in the year-earlier period.

Let us take a look at what's in store for biotech/drug stocks GILD, PRGO, VTRS, SAGE and IOVA, which are scheduled to report on Nov 7.

Broadcom Inc. and Perrigo Company plc are two companies providing impressive dividend growth to their shareholders. Perrigo Company is a smaller pharmaceutical company focusing on over-the-counter healthcare products, while Broadcom is a semiconductor behemoth with a software business segment set to grow. Both are expecting attractive growth going forward, which could further support even more dividend growth and possibly capital appreciation in the future.